2021-06-08-深交所-华东医药_2021年第一季度报告全文（英文版）_38页_516kb

报告摘要

Huadong Medicine Co., Ltd. - First Quarterly Report 2021 Summary

Core Content

Huadong Medicine Co., Ltd. issued its first quarterly report for 2021, covering financial performance, shareholder structure, and operational highlights. The report outlines the company's financial results, significant events, and strategic initiatives for the quarter.

Key Financial Data and Indicators

Item	Current Reporting Period (yuan)	Same Period Last Year (yuan)	Change (%)
Operating Revenue	8,896,632,277.36	8,598,069,911.29	3.47%
Net Profit (Shareholders)	758,380,756.56	1,147,278,457.64	-33.90%
Net Profit (After Non-Recurring)	695,792,411.78	856,930,262.10	-18.80%
Net Cash Flow from Operating Activities	302,314,164.48	218,779,623.89	38.18%
Basic Earnings per Share	0.4334	0.6557	-33.90%
Weighted Average ROE	5.04%	8.89%	-3.85%
Total Assets	26,096,806,585.74	24,201,348,154.75	7.83%
Net Assets (Shareholders)	15,266,793,123.79	14,619,821,308.60	4.43%

Non-Recurring Gains/Losses

Gains on disposal of non-current assets: 15,675.63 yuan
Government grants (non-operating): 76,459,624.41 yuan
Other non-operating income/expenditure: -2,351,230.65 yuan
Total non-recurring gains/losses: 62,588,344.78 yuan

Shareholder Information

Total common shareholders: 168,355
Top 10 shareholders:
- China Grand Enterprises, Inc. (41.77%, 730,938,157 shares)
- Hangzhou Huadong Medicine Group Co., Ltd. (15.69%, 274,620,000 shares)
- Hong Kong Securities Clearing Company Ltd. (1.82%, 31,905,503 shares)
- China Securities Finance Co., Ltd. (1.27%, 22,186,818 shares)
- Huaxia Life Insurance Co., Ltd. - own funds (0.61%, 10,713,280 shares)
- National Social Security Fund Portfolio 602 (0.45%, 7,926,311 shares)
- National Social Security Fund Portfolio 503 (0.34%, 6,000,000 shares)
- Basic Endowment Insurance Fund Portfolio 15041 (0.30%, 5,253,350 shares)
- #Yang Yushan (0.29%, 5,000,000 shares)
- #Chen Shaoming (0.22%, 3,764,388 shares)

Changes in Financial Data

Item	Current Period (yuan)	Previous Period (yuan)	Change (%)	Notes
Accounts Receivable Financing	578,065,866.37	828,659,217.25	-30.24%	Increase in notes collection
Advance Receipts	356,122,946.06	250,916,482.07	41.93%	Increase in prepayment
Other Receivables	116,804,796.17	83,073,823.45	40.60%	Increase in provisional payments
Other Current Assets	51,201,382.80	85,654,691.58	-40.22%	Decrease in input VAT
Other Non-Current Assets	931,645,777.92	712,069,194.08	30.84%	Increase in equipment and intangible asset prepayment
Notes Payable	981,406,149.63	554,336,058.71	77.04%	Increase in bill payment
Long Term Loan	209,937,945.01	151,611,367.86	38.47%	Increase in long-term loans
Management Expenses	277,542,542.53	196,704,190.05	41.10%	Salary increase
Financial Expenses	8,531,468.21	15,759,648.63	-45.87%	Increase in interest income, decrease in financing costs
Gains on Assets Disposal	304,336.80	306,269,024.44	-99.90%	Disposal of Western European market distribution rights
Investment Income	-26,664,999.81	-1,256,335.99	-2022.44%	Increase in discount interest, decrease in joint venture profits
Other Income	76,459,624.41	20,044,478.23	281.45%	Increase in government subsidies
Net Profit	774,473,984.45	1,153,425,789.92	-32.85%	Price reduction of products, decreased gross profit

Operational Highlights

Operating Revenue: Increased by 3.47% year-on-year to 8.897 billion yuan.
Net Profit: Declined by 33.90% year-on-year to 758 million yuan.
Core Subsidiary (Zhongmei Huadong): Operating revenue of 3.092 billion yuan, down 14.58% year-on-year but up 38.61% month-on-month; net profit of 730 million yuan, down 14.60% year-on-year but up 85.30% month-on-month.
Pharmaceutical Business: Showed recovery growth, with operating income up 16.0% year-on-year.
Medical Aesthetics Business: Continued to grow, with the income from the holding subsidiary Huadong Ningbo medical aesthetics business up 63.3%.
Sinclair (UK): Operating income increased by 12.7% year-on-year, despite the ongoing overseas pandemic.
R&D Investment: Total investment in pharmaceutical R&D reached 283 million yuan, up 2.3% year-on-year.

Strategic Developments

The company accelerated the transformation of its business units from cost centers to profit centers.
It deepened innovation and international transformation efforts.
It focused on the integration of resources and the development of new products and technologies.

Investment Activities

Equity Investment in Novacyte Therapeutics: 35 million yuan, with preferential transfer rights for products developed before 2026.
Acquisition of DoerBio: 487.5 million yuan for 75% equity, becoming the controlling shareholder.
Investment in RAPT Therapeutics (Hong Kong): 20.207 million yuan, with 183,002 shares held, accounting for 0.74% of total shares.

Investor Relations

The company conducted several investor exchange meetings in February and March 2021.
Details of these meetings can be found on the Shenzhen Stock Exchange Interactive Easy website and cninfo.com.cn.

Summary of Key Points

The company experienced a significant year-on-year decline in net profit, primarily due to price reductions and policy impacts.
Non-recurring gains/losses had a notable effect on financial results.
The company maintained a stable shareholder structure with no major changes in share repurchase or commitments.
Strategic initiatives in pharmaceutical and medical aesthetics sectors were advanced, with a focus on innovation and international expansion.
The company continued to develop new products and technologies, enhancing its competitive position.

展开完整摘要